Two major causes of morbidity and mortality in bone marrow transplant recipients are infection and acute graft versus host disease, which may be difficult to distinguish clinically and may also occur simultaneously.' There would be obvious value for any laboratory investigation that could be used in the differential diagnosis and monitoring of these complications.
Increased concentrations of serum IgE have been reported after allogeneic bone marrow transplant,2 and in some patients the rise accompanied clinical and biochemical evidence of acute graft versus host disease. Later studies3 suggested that monitoring serum IgE concentrations might be helpful in reaching an early diagnosis of acute graft versus host disease. The IgE response is T cell dependent, however, and it is possible that disturbed T cell regulation resulting from infection, particularly viral, might also be associated with raised serum IgE concentrations in the bone marrow, transplant recipients. If this were so, a raised serum IgE would not be a specific and early indicator of acute graft versus host disease.
In the present study serum IgE concentrations were investigated in bone marrow transplant recipients in relation to graft versus host disease and infection.
Patients and methods
Forty episodes of infection, acute graft versus host Accepted for publication 2 December 1983 disease, or both, were clearly documented in 25 of 35 bone marrow transplant recipients studied. Patients had been transplanted for acute leukaemia (12) , aplastic anaemia (4), or inborn errors of metabolism (9) . There were 23 children (age range 11 months-15 years) and two adults (both with acute leukaemia). Serum IgE concentrations were also measured in 16 patients with chronic graft versus host disease, diagnosed clinically and histologically, who had no evidence of infection.
IgE was measured by the Phadebas IgE PRIST method (Pharmacia Diagnostics AB, Uppsala, Sweden).
Serum samples were taken before transplantation and weekly after transplantation until discharge unless infection or graft versus host disease developed, when samples were taken on alternate days. Serum samples were taken from patients with chronic graft versus host disease when they were reviewed as outpatients (range 3 months-4 years after transplantation). Tables 1 and 2 respectively.
Results

Serum
In all but three of the bacterial, fungal, and pro-Increased serum IgE concentrations after bone marrow transplantation Figure. The incremental rise in IgE was derived by subtracting the value before transplantation from the maximum value observed during an episode. Most of the patients were children with pretransplantation values below 5 IU/ml. In all episodes monitored the IgE concentrations returned group.bmj.com on July 7, 2017 -Published by http://jcp.bmj.com/ Downloaded from serum IgE concentrations in acute graft versus host disease and unchanged values in chronic disease. ' The maximum concentration seen in the present study was only 307 IU/ml, however, whereas Geha et al' reported values up to 9500 IU/ml. Differences in patient management and treatment as a factor in modifying the IgE response cannot be excluded.
In the present study raised serum IgE concentrations seen in many infections with or without graft versus host disease. A number of infections have been reported to be associated with raised serum IgE.4-6 In one study ' various 
